Miguel Arquez

Miguel Arquez

Auto-generated profile, based on publicly available information

Miguel Arquez

Hosp Univ St Joan, Dept Radiat Oncol, Tarragona, Spain

Research Focus & Metrics

Academic Career Length

21Years (2006-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 January 2020 in Expert Systems with Applications
Verified
Journal Article
Closed access
Vivek kumar SinghVivek kumar Singh
Vivek kumar Singh
HRHatem A. Rashwan
Hatem A. Rashwan
SRSantiago Romani
Santiago Romani
FAFarhan Akram
Farhan Akram
NPNidhi Pandey
Nidhi Pandey
JTJordina Torrents-Barrena
Jordina Torrents-Barrena

1 March 2020 in Reports of Practical Oncology and Radiotherapy
Verified
Journal Article
Closed access
LRLaura Torres Royo
Laura Torres Royo
GAGabriela Antelo
Gabriela Antelo
MPMiguel Árquez Pianetta
Miguel Árquez Pianetta
MPMeritxell Arenas Prat
Meritxell Arenas Prat
Radiotherapy (RT) has always been a mainstay for malignant tumors therapy, but it is also used for benign pathology. The application of low or intermediate doses of RT has been widely studied. This topic was presented and discussed in the last XX GOCO (Grup Oncològic Català-Occità) meeting. The aim of this article is to review the indications of low dose irradiation (LD-RT), total dose and different fractionations, the public to whom it can be directed, and to offer an analysis about secondary effects. We believe it can be useful not only for radiation oncologists, but for other physicians to consider this option for future patients.

1 January 2017 in Journal of Contemporary Brachytherapy
Verified
Journal Article
Open access
Meritxell ArenasMeritxell Arenas
Meritxell Arenas
SSSebastia Sabater
Sebastia Sabater
ASAndreu Sintas
Andreu Sintas
MAMonica Arguís
Monica Arguís
VHVíctor Hernández
Víctor Hernández
DPDoménec Puig
Doménec Puig
Purpose: Skin cancer is the most common tumor in the population. There are different therapeutic modalities. Brachytherapy is one of the techniques used, in which it is necessary to build customized moulds for some patients. Currently, these moulds are made by hand using rudimentary...

26 September 2018
Verified
Book Chapter
Closed access
PDF file
VSVivek Kumar Singh
Vivek Kumar Singh
SRSantiago Romani
Santiago Romani
HRHatem A. Rashwan
Hatem A. Rashwan
FAFarhan Akram
Farhan Akram
NPNidhi Pandey
Nidhi Pandey
DPDomenec Puig
Domenec Puig

1 January 2006
Verified
Conference Paper
Open access
HBH. Bredin
H. Bredin
AMA. Miguel
A. Miguel
IWI.H. Witten
I.H. Witten
GCGérard Chollet
Gérard Chollet
We describe an algorithm that detects a lack of correspondence between speech and lip motion by detecting and monitoring the degree of synchrony between live audio and visual signals. It is simple, effective, and computationally inexpensive; providing a useful degree of robustness against basic replay attacks and against speech or image forgeries. The method is based on a cross-correlation analysis between two streams of features, one from the audio signal and the other from the image sequence. We argue that such an algorithm forms an effective first barrier against several kinds of replay attack that would defeat existing verification systems based on standard multimodal fusion techniques. In order to provide an evaluation mechanism for the new technique we have augmented the protocols that accompany the BANCA multimedia corpus by defining new scenarios. We obtain 0% equal-error rate (EER) on the simplest scenario and 35% on a more challenging one

1 May 2017 in Reports of Practical Oncology and Radiotherapy
Verified
Journal Article
Closed access
IHIvan Henriquez
Ivan Henriquez
DPDavid Parada
David Parada
PGPablo Gallardo
Pablo Gallardo
MGMarina Gascón
Marina Gascón
ABArnau Besora
Arnau Besora
Meritxell ArenasMeritxell Arenas
Meritxell Arenas
Ki-67 is a proliferation marker in prostate cancer. A prognostic RNA signature was developed to characterize prostate cancer aggressiveness. The aim was to evaluate prognostic correlation of CCP and Ki-67 with biochemical failure (BF), and survival in high-risk prostate cancer patients (pts) treated with radiation therapy (RT). CCP score and Ki-67 were derived retrospectively from pre-treatment paraffin-embedded prostate cancer tissue of 33 men diagnosed from 2002 to 2006. CCP score was calculated as an average expression of 31 CCP genes. Ki-67 was determined by IHC. Single pathologist evaluated all tissues. Factors associated to failure and survival were analyzed. Median CCP score was 0.9 (-0-1 - 2.6). CCP 0: 1 pt; CCP 1: 19 pts; CCP 2: 13 pts. Median Ki-67 was 8.9. Ki-67 cutpoint was 15.08%. BF and DSM were observed in 21% and 9%. Ki-67 ≥ 15% predicted BF (p = 0.043). With a median follow-up of 8.4 years, 10-year BF, OS, DM and DSM for CCP 1 vs. CCP 2 was 76-71% (p = 0.83), 83-73% (p = 0.86), 89-85% (p = 0.84), and 94-78% (p = 0.66). On univariate, high Ki-67 was correlated with BF (p = 0.013), OS (p = 0.023), DM (p = 0.007), and DSM (p = 0.01). On Cox MVA, high Ki-67 had a BF trend (p = 0.063). High CCP score was not correlated with DSM. High Ki-67 significantly predicted outcome and provided prognostic information. CCP score may improve accuracy stratification. We did not provide prognostic correlation of CCP and DSM. It should be validated in a larger cohort of pts.